What happened with DOCS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Doximity connects U.S. medical professionals through tools for communication, medical news and patient visits. Pharmaceutical manufacturers and health systems are its main paying customers. They buy sponsored content and marketing services to reach selected groups of professionals: drugmakers buy programs for individual brands, while health systems buy them for particular service lines. Marketing prices depend on the audience targeted and the services purchased, and customers can buy directly or through agencies.
Most revenue comes from subscriptions. Beyond marketing, health systems and recruiting firms pay to post jobs or message potential candidates. Customers also subscribe to telehealth, on-call scheduling and clinical AI tools, including Ask and Scribe. Its Curative Talent business earns hourly or placement fees from health systems for temporary staffing and permanent hires.
The business depends on professionals continuing to use the platform and keeping their profiles accurate, which helps paying customers reach relevant audiences and candidates. Pharmaceutical customers supply a significant share of revenue but typically do not sign long-term contracts; one customer also represents a substantial share. Doximity must handle health information under HIPAA and other privacy rules, and its services must allow customers to comply with healthcare laws.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Doximity’s results hinge on pharmaceutical and health-system marketing spending and physician engagement; watch WebMD’s Medscape and OpenEvidence, important rivals for marketing access absent from this list.
Phreesia competes with Doximity for life sciences companies’ spending on reaching healthcare audiences: its Network Solutions delivers personalized messages to patients and providers, while Doximity sells targeted sponsored content. Watch Phreesia’s Network Solutions revenue for spending on this audience access.
Ziff Davis competes with Doximity for healthcare advertising and performance-marketing budgets through its Health & Wellness media business, while Doximity sells sponsored content to pharmaceutical manufacturers and health systems. Watch advertising and performance-marketing revenue in Health & Wellness rather than Ziff Davis’s unrelated subscription businesses.
Veeva Systems and Doximity both draw on pharmaceutical commercialization spending: Veeva sells commercial software and data to life sciences companies, while Doximity sells pharmaceutical marketing subscriptions by brand. Veeva’s Commercial Solutions revenue is the line to watch for this shared spending exposure, rather than its R&D and quality software.
American Well competes with Doximity for health systems’ telehealth technology spending: its Amwell Platform and Doximity’s Workflow Solutions sell digital-care tools through subscriptions. Watch Amwell’s platform subscriptions to health systems for competition facing Doximity’s telehealth tools.
Teladoc Health competes with Doximity for health systems’ virtual-care technology budgets, selling connected-care offerings where Doximity sells telehealth tools. Watch hospital and health-system demand within Teladoc’s Integrated Care business, rather than its consumer-focused BetterHelp therapy business.
Teladoc Health, Inc. earningsTDOC
Teladoc Health’s Integrated Care results will show whether hospitals and health systems are still buying virtual-care technology from a business competing with Doximity’s telehealth tools.
Focus on Teladoc Health’s Integrated Care business, not its consumer-focused BetterHelp therapy business. Stronger Integrated Care demand would show that health systems remain willing to pay for virtual-care tools, supporting the budget pool Doximity competes for; weaker demand would suggest pressure on those purchases, but would not prove Doximity is losing customers. The takeaway is whether the health-system budget they share is holding up or tightening.
Doximity, Inc. earningsThis company
Doximity sells subscriptions for healthcare marketing, hiring and workflow tools, and its report will show whether existing customers are buying more and new customers are adding to growth.
Check where subscription growth comes from. Doximity previously said existing-customer expansion was led by marketing customers adding brands and service lines, with new subscription customers also contributing. If both sources grow, existing customers are broadening their spend and new customers are joining; if expansion weakens or new-customer additions lag, growth relies more on a smaller group of customers spending more. Then check net revenue retention, which tracks subscription revenue after renewals, expansion, contraction and churn among existing customers: a decline means expansion is not offsetting reductions and losses. The conclusion is whether growth has support from both customer expansion and new additions.
